Share on LinkedInShare on LinkedIn

ARTICLE · 31 AUGUST 2021

COVID-19 rapid antigen tests: complying with advertising and supply requirements

Piper Alderman
Piper Alderman
Contributor
Piper Alderman

Piper Alderman

Helping shape the future of business in Australia with practical, commercial and cutting-edge legal...

View firm profile
Explore more from Piper Alderman

With rising COVID-19 infections, TGA issued new guidance on the public advertising and supply of rapid antigen tests.

AustraliaMedia, Telecoms, IT, Entertainment

Amidst rising COVID-19 infections across the nation, the Therapeutic Goods Administration has issued new guidance on the public advertising and supply of COVID-19 rapid antigen tests.

Any sponsor of COVID-19 rapid antigen tests must comply with strict advertising requirements and conditions imposed on the supply of these tests.

Advertising of rapid antigen tests

Publically accessible advertising of COVID-19 rapid antigen tests is regulated by the Therapeutic Goods Advertising Code (No. 2) 2018 (Cth) (Advertising Code) and the Therapeutic Goods Act 1989 (Cth) (Therapeutic Goods Act). In particular, any representation that refers to a serious disease, being COVID-19 in this instance, must be approved by the Therapeutic Goods Administration before being used in an advertisement.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from